Urology Exams

مشاركات: 11468
اشترك في: الخميس إبريل 04, 2013 10:28 pm

Re: Urology Exams

مشاركةبواسطة دكتور كمال سيد » السبت فبراير 09, 2019 5:45 pm

https://radiopaedia.org/cases/staghorn- ... al-calculi

Patient Data
GENDER: Female

Presentation
Female with hematuria and recurrent urinary infections

X-RAY
صورة
Frontal
Staghorn calculi (coral calculi) in left kidney.
(The renal calculus fills and conforms to the left renal calices, resembling the horns of a deer (staghorn calculus

Case Discussion
Staghorn calculi (also sometimes called coral calculi) obtain their characteristic shape by forming a cast of the renal pelvis and calices, thus resembling the horns of a stag.
صورة

مشاركات: 11468
اشترك في: الخميس إبريل 04, 2013 10:28 pm

Re: Urology Exams

مشاركةبواسطة دكتور كمال سيد » الثلاثاء فبراير 12, 2019 9:19 pm

Scrolling Quizzes

Which of the following is/are true about renal calculi?

You can stop the scroller at any time by moving your mouse over it.

Ready?
Quiz:

Which of the following is/are true about renal calculi?

1. The vast majority are composed of calcium oxalate.

2. Uric acid stones may be difficult to visualize on radiographs.

3. A calculus in the renal pelvis is called a "Jackstone Calculus."


Answers below:

Answers:

Which of the following is/are true about renal calculi?

1. The vast majority are composed of calcium oxalate. TRUE. About 85%.

2. Uric acid stones may be difficult to visualize on radiographs. TRUE.

3. A calculus in the renal pelvis is called a "Jackstone Calculus." FALSE. A "Jackstone Calculus" occurs in the bladder.
صورة

مشاركات: 11468
اشترك في: الخميس إبريل 04, 2013 10:28 pm

Re: Urology Exams

مشاركةبواسطة دكتور كمال سيد » الأحد مارس 24, 2019 9:34 pm

صورة

مشاركات: 11468
اشترك في: الخميس إبريل 04, 2013 10:28 pm

Re: Urology Exams

مشاركةبواسطة دكتور كمال سيد » الاثنين مارس 25, 2019 11:24 pm

Novel Concepts in the Management of RCC
https://www.medscape.org/viewarticle/900287

ارجو التسجيل في medscape.org

Educational Impact Challenge
The goal of this activity is to discuss the evolving role of cancer immunotherapy in renal cell carcinoma (RCC).

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Question 1 of 5


Which of the following patients with advanced renal cell carcinoma (RCC) would be the best candidate for treatment with nivolumab + ipilimumab according to the 2018 US Food and Drug Administration (FDA) indication?

A patient whose disease has progressed following treatment with sunitinib

A patient whose disease has progressed following treatment with nivolumab

A newly diagnosed patient with poor-risk disease

A newly diagnosed patient with favorable-risk disease

Question 2 of 5


What did the phase 3 IMmotion151 trial examine?

Combination anti–programmed cell death ligand-1 (PD-L1) + chemotherapy

Combination anti–PD-L1 + anti–vascular endothelial growth factor (VEGF)

Combination anti–PD-L1 + anti–cytotoxic T-lymphocyte-associated protein-4 (CTLA-4)

Combination anti-PD-L1 + anti–programmed cell death-1 (PD-1)

Question 3 of 5


Results of KEYNOTE-427 suggest which of the following in patients with advanced RCC?

Monotherapy with PD-1 inhibition may be feasible in the first-line setting

Combination therapy with PD-1 inhibition + VEGF inhibition may have a role in the first-line setting

Combination therapy with PD-1 inhibition + VEGF inhibition may have a role in the second-line setting

Monotherapy with PD-1 inhibition should be further explored in the second-line setting

Question 4 of 5


How confident are you in prescribing immunotherapy for your patients with advanced RCC? (Select ranking from 1 [Not confident] to 5 [Very confident])

1 - Not confident

2

3

4

5 - Very confident

Question 5 of 5


Which of the following most closely describes your practice setting?

Academic, specializing in RCC

Academic, specializing in other cancers

Community, specializing in RCC

Community, covering a range of cancers

SAVE AND PROCEED

Educational Impact Challenge
The goal of this activity is to discuss the evolving role of cancer immunotherapy in renal cell carcinoma (RCC).

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Question 1 of 5


Which of the following patients with advanced renal cell carcinoma (RCC) would be the best candidate for treatment with nivolumab + ipilimumab according to the 2018 US Food and Drug Administration (FDA) indication?

A patient whose disease has progressed following treatment with sunitinib

A patient whose disease has progressed following treatment with nivolumab

A newly diagnosed patient with poor-risk disease

A newly diagnosed patient with favorable-risk disease

Question 2 of 5


What did the phase 3 IMmotion151 trial examine?

Combination anti–programmed cell death ligand-1 (PD-L1) + chemotherapy

Combination anti–PD-L1 + anti–vascular endothelial growth factor (VEGF)

Combination anti–PD-L1 + anti–cytotoxic T-lymphocyte-associated protein-4 (CTLA-4)

Combination anti-PD-L1 + anti–programmed cell death-1 (PD-1)

Question 3 of 5


Results of KEYNOTE-427 suggest which of the following in patients with advanced RCC?

Monotherapy with PD-1 inhibition may be feasible in the first-line setting

Combination therapy with PD-1 inhibition + VEGF inhibition may have a role in the first-line setting

Combination therapy with PD-1 inhibition + VEGF inhibition may have a role in the second-line setting

Monotherapy with PD-1 inhibition should be further explored in the second-line setting

Question 4 of 5


How confident are you in prescribing immunotherapy for your patients with advanced RCC? (Select ranking from 1 [Not confident] to 5 [Very confident])

1 - Not confident

2

3

4

5 - Very confident

Question 5 of 5


Which of the following most closely describes your practice setting?

Academic, specializing in RCC

Academic, specializing in other cancers

Community, specializing in RCC

Community, covering a range of cancers

SAVE AND PROCEED
https://www.medscape.org/viewarticle/900287
صورة

مشاركات: 11468
اشترك في: الخميس إبريل 04, 2013 10:28 pm

Re: Urology Exams

مشاركةبواسطة دكتور كمال سيد » الاثنين مارس 25, 2019 11:25 pm

Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer

Educational Impact Challenge
The goal of this activity is to discuss the most up-to-date use of immunotherapy in the treatment of patients with advanced bladder cancer.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Question 1 of 5


A 59-year-old man is diagnosed with metastatic bladder cancer. He has a creatinine clearance (CrCl) of 50 mL/min and grade 2 peripheral neuropathy.
Which of the following is the best next step in his treatment?

Treat with cisplatin-based chemotherapy

Treat with pembrolizumab or atezolizumab

Perform tumor mutational burden (TMB) testing

Perform programmed death-ligand 1 (PD-L1) testing

Question 2 of 5


A 77-year-old woman with metastatic bladder cancer experienced tumor progression following treatment with cisplatin-based chemotherapy.
Which of the following is the best next step?

Treat with a checkpoint inhibitor

Treat with a tyrosine kinase inhibitor (TKI)

Perform PD-L1 testing

Perform TMB testing

Question 3 of 5


Which of the following is true about the identification and management of immune-related adverse events (irAEs) associated with immune checkpoint inhibition?

They occur extremely rarely and can be predicted in a majority of cases

The oncologist can manage them, similar to chemotherapy-related adverse events

The multidisciplinary team must work together to manage them

They are usually managed with over-the-counter treatments the nurse can suggest

Question 4 of 5


How confident are you in identifying patients with advanced bladder cancer who are appropriate candidates for therapy with immune checkpoint inhibitors? (Select ranking from 1 [Not confident] to 5 [Very confident])

1 - Not confident

2

3

4

5 - Very confident

Question 5 of 5


Which of the following most closely describes your practice setting?

Academic, specializing in bladder cancer

Academic, specializing in other cancers

Community, specializing in bladder cancers

Community, covering a range of cancers

SAVE AND PROCEED

https://www.medscape.org/viewarticle/902370
صورة

مشاركات: 11468
اشترك في: الخميس إبريل 04, 2013 10:28 pm

Re: Urology Exams

مشاركةبواسطة دكتور كمال سيد » الثلاثاء إبريل 16, 2019 11:07 pm

صورة

مشاركات: 11468
اشترك في: الخميس إبريل 04, 2013 10:28 pm

Re: Urology Exams

مشاركةبواسطة دكتور كمال سيد » الأربعاء إبريل 17, 2019 6:02 pm

UROLOGY Multiple-choice questions
http://www.imop.gr/en/uroelearning-uro-exams
صورة

مشاركات: 11468
اشترك في: الخميس إبريل 04, 2013 10:28 pm

Re: Urology Exams

مشاركةبواسطة دكتور كمال سيد » الخميس إبريل 18, 2019 6:51 pm

صورة

مشاركات: 11468
اشترك في: الخميس إبريل 04, 2013 10:28 pm

Re: Urology Exams

مشاركةبواسطة دكتور كمال سيد » الخميس إبريل 18, 2019 8:38 pm

صورة

السابق

العودة إلى UROLOGY -- جراحة المسالك البولية

الموجودون الآن

المستخدمون المتصفحون لهذا المنتدى: لا يوجد أعضاء مسجلين متصلين و 1 زائر

cron